Objective: To characterize malpractice trends related to active surveillance (AS) as a treatment strategy across cancers.
Background: Active surveillance is increasingly considered a viable management strategy for low-risk cancers. Since a subset of AS cases will progress, metastasize, or exhibit cancer-related mortality, a significant barrier to implementation is the perceived risk of litigation from missing the window for cure.